(NASDAQ: MESO) Mesoblast's forecast annual revenue growth rate of 132.38% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Mesoblast's revenue in 2025 is $17,198,000.On average, 1 Wall Street analysts forecast MESO's revenue for 2026 to be $137,852,466,040, with the lowest MESO revenue forecast at $137,852,466,040, and the highest MESO revenue forecast at $137,852,466,040.
In 2027, MESO is forecast to generate $207,047,492,169 in revenue, with the lowest revenue forecast at $207,047,492,169 and the highest revenue forecast at $207,047,492,169.